Surface chemistry dependent toxicity of inorganic nanostructure glycoconjugates on bacterial cells and cancer cell lines

© 2022 Elsevier B.V.Surface functionalized nanostructures have outstanding potential in biological applications owing to their target-specific design. In this study, we utilized laboratory synthesized carbohydrate-derivatives (i.e., galactose, mannose, lactose, and cellobiose derivatives) for aqueous one-pot synthesis of gold (Au) and silver (Ag) nanostructure glycoconjugates (NSs), and iron metal-organic framework glycoconjugates (FeMOFs). This work aims to test whether differences in the surface chemistry of the inorganic nanostructures play roles in revealing their toxicities towards bacterial cells and cancerous cell lines. As of the first step, biological activity of AuNSs, AgNSs, and FeMOFs were tested against a variety of gram (−) and gram (+) bacterial strains, where AgNSs possessed moderate to high antibacterial activities against all the tested bacterial strains, while AuNSs and FeMOFs showed their bacterial toxicity mostly depending on the strain. Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) determination studies were performed for the nanostructure glycoconjugates, for which μg/mL MBC values were obtained such as (Cellobiose p-aminobenzoic acid_AgNS) CBpAB_AgNS gave 50 μg/mL MBC value for P.aeruginosa and S.kentucy. The activity of selected sugar ligands and corresponding glycoconjugates were further tested on MDA-MB-231 breast cancer and A549 lung cancer cell lines, where selective anticancer activity was observed depending on the surface chemistry as well. Besides, D-penicillamine was introduced to galectin specific sugar ligand coated AuNS glycoconjugates, which showed very strong anticancer activities even at low doses. Overall, the importance of this work is that the surface chemistry of the inorganic nanostructures can be critical to reveal their toxicity towards bacterial cells and cancerous cell lines

Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Obesity Study)

Background: Obesity is the main obstacle for metabolic control in patients with type 2 diabetes. Turkey has the highest prevalence of obesity and type 2 diabetes in Europe. The effect of obesity on the metabolic control, and the macro-and microvascular complications of patients are not apparent. Objectives: This nationwide survey aimed to investigate the prevalence of overweight and obesity among patients with type 2 diabetes and to search for the impact of obesity on the metabolic control of these patients. We also investigated the independent associates of obesity in patients with type 2 diabetes. Methods: We consecutively enrolled patients who were under follow-up for at least 1 year in 69 tertiary healthcare units in 37 cities. The demographic, anthropometric, and clinical data including medications were recorded. Patients were excluded if they were pregnant, younger than 18 years, had decompensated liver disease, psychiatric disorders interfering with cognition or compliance, had bariatric surgery, or were undergoing renal replacement therapy. Results: Only 10% of patients with type 2 diabetes (n = 4,648) had normal body mass indexes (BMI), while the others were affected by overweight (31%) or obesity (59%). Women had a significantly higher prevalence of obesity (53.4 vs. 40%) and severe obesity (16.6 vs. 3.3%). Significant associations were present between high BMI levels and lower education levels, intake of insulin, antihypertensives and statins, poor metabolic control, or the presence of microvascular complications. Age, gender, level of education, smoking, and physical inactivity were the independent associates of obesity in patients with type 2 diabetes. Conclusion: The TEMD Obesity Study shows that obesity is a major determinant of the poor metabolic control in patients with type 2 diabetes. These results underline the importance of prevention and management of obesity to improve health care in patients with type 2 diabetes. Also, the results point out the independent sociodemographic and clinical associates of obesity, which should be the prior targets to overcome, in the national fight with obesity. (c) 2019 The Author(s) Published by S. Karger AG, Base

Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study)

Aims: Turkey has the highest prevalence of diabetes in Europe. It is therefore essential to know the overall cardiovascular risk and reveal the predictors of metabolic control in Turkish adults with diabetes mellitus